Overview: What dose escalation could mean for GEP-NET patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present a challenging therapeutic landscape, often requiring targeted strategies that control tumor growth and symptom burden. Somatostatin analogs (SSAs), such as octreotide and lanreotide, have been foundational therapies, known for stabilizing disease and reducing hormone-related symptoms. However, emerging discussions in the field…